COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pozzi Forceps in Intrauterine Insemination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03435809
Recruitment Status : Recruiting
First Posted : February 19, 2018
Last Update Posted : January 27, 2020
Information provided by (Responsible Party):
CHU de Quebec-Universite Laval

Brief Summary:
Many infertility and subfertility issues are treated nowadays with intrauterine inseminations. This is a minimally invasive technique that consists in placing sperm into a woman's uterus. Inseminations have only a fair success rate despite advances in technology ( 7 % per cycle). The goal of this study is to find an easy intervention that could help with success rate. Some studies are showing that the use of Pozzi tenaculum forceps might increase rates of pregnancy following intrauterine inseminations. In order to study the impact of this intervention, we are conducting a randomized controlled trial comparing the rate of term live births after IUI between patients who had their treatment done with a pozzi tenaculum forceps and those who had their treatment done without a tenaculum forceps.

Condition or disease Intervention/treatment Phase
Infertility Insemination Procedure: Intrauterine insemination Not Applicable

Detailed Description:

Once the initial investigations are done, an oral treatment is started on the first cycle if medically indicated.

At mid-cycle, patients undergo a transvaginal ultrasound looking for follicles' maturation. This ultrasound's goal is to detect ovulation and plan the IUI. If no follicle is detected, the transvaginal ultrasound is repeated later. If there is no luteinizing hormone (LH) peak detected upon ovulation urine test, there will be an ovulation induction with human chorionic gonadotropin (hCG) based depending on patient's age, number and size of detected follicles. Subcutaneous hCG or intramuscular hCG can be used. A cycle can be cancelled if there is no ovulation or if there is ovarian hyperstimulation.

During ovulation, semen analysis is performed, looking at sperm volume, sperm concentration and mobility. Then, semen is treated with a density gradient or with centrifugation. Isolated sperm are diluted in 0.5 to 1 mL of media and maintained in an incubator at a 37 º C temperature until insemination. The laboratory performs a second analysis on the washed semen in order to obtain the most accurate measures. If donor's semen is used, the andrology laboratory prepares the specimen and then processes with the semen analysis.

Patients are inseminated the day after a spontaneous LH peak or 24-36h after ovulation induction. For those who are randomized to the intervention group, a pozzi tenaculum forceps will be applied and clamped horizontally to the anterior cervical labrum with only a single click and mild traction will be applied in another to decrease the uterocervical angle. When no tenaculum is applied, motion will be mimicked without actual tissue prehension. Patients randomized to the control group will only have a tenaculum forceps applied in cases where the IUI is not feasible otherwise by the gynecologist. Indeed, it is sometimes necessary, when the cervical anatomy does not allow for easy pass of the catheter, for a pozzi tenaculum forceps to be used in order to insert the insemination catheter properly in the uterine cavity. In that case, tenaculum use will be recorded in the patient's file. No cervical insemination is allowed. Insemination is performed with flexible catheters and care is taken to avoid touching the uterine fundus with the catheter tip. There are multiple catheters available in the gynecology clinic, namely catheters The Curve (Cooper Surgical, Berlin), Shapeable IUI Catheter (Thomas Medical, Indianapolis) and Mini space (Laboratory C.C.D., Paris). After the intervention, patients are instructed to lie flat for 10 minutes after which they go home until next appointment.

Intercourse is allowed following IUI treatments. Patients are instructed to perform a urinary pregnancy test at home to weeks after the IUI, which will be provided to them. If the test is positive, patients are scheduled for a transvaginal ultrasound on week #7 of amenorrhea to confirm proper intrauterine pregnancy evolution. When pregnancy is confirmed, patients are referred to an physician for obstetrical follow-up.

In case of treatment failure, patients go on with ovulation induction or stimulation for the next cycle as previously prescribed by the gynecologist at mid-cycle ultrasound, if indicated. Dosages of ovarian stimulation medication may be modified, at physician's discretion, in order to optimize response to treatment according to the usual indications (ovarian hyperstimulation, side effects, poor response, etc.) Patients will be followed for 3 cycles and, if need be, can receive subsequent IUI treatments outside research protocol.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Control Study on the Impact of a Pozzi Tenaculum Forceps Use on the Success Rate of Intrauterine Insemination (IUI)
Actual Study Start Date : June 1, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Active Comparator: Pozzi for intrauterine insemination
Treatment done with a pozzi tenaculum forceps
Procedure: Intrauterine insemination
Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination

Active Comparator: No Pozzi for intrauterine insemination
Treatment done without a tenaculum forceps
Procedure: Intrauterine insemination
Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination

Primary Outcome Measures :
  1. Rate of live births [ Time Frame: At the end of 1 cycle (approximately 28 days) ]
    Term delivery resulting from an intrauterine insemination cycle

Secondary Outcome Measures :
  1. Clinical rate of pregnancy [ Time Frame: At the end of 1 cycle (approximately 28 days) ]
    Positive urinary pregnancy test ou blood test (b-hcG)

  2. Patients' global satisfaction [ Time Frame: 15 minutes after the intervention ]
    In regards of the treatment they received, yes/no questions Are you satisfied with the treatment you received? Do you think this treatment is an reasonable option of treatment?

  3. Pain Level [ Time Frame: 15 minutes after the intervention ]
    Visual analog scale On a scale from 0-10 with intermediate values, 10 being the worst pain ever and 0 being no pain at all.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Infertility :Defined as no pregnancy after one year of regular unprotected vaginal intercourse
  • Infertility secondary to endometriosis, to a mild to moderate male factor, to an ovulatory dysfunction, an unexplained infertility or any other known medical indication for IUI.
  • Intrauterine insemination with a partner's semen sample or a donor sample
  • First IUI treatment or first treatment since last pregnancy
  • Ovulation induction with letrozole medication
  • Being able to speak and understand French

Exclusion Criteria:

  • Bilateral tubal occlusion
  • Active pelvic infection
  • < 1 X 10^6 mobile sperm on semen analysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03435809

Layout table for location contacts
Contact: Stephanie Dufour, PGY3 418-525-4444

Layout table for location information
CHUL Centre Mère Enfant Soleil - CHU de Quebec Recruiting
Quebec, Canada, G1V 4G2
Contact: Marie-Ève Bergeron, MD    418-525-4444 ext 42777   
Principal Investigator: Stephanie Dufour, MD         
Sponsors and Collaborators
CHU de Quebec-Universite Laval
Layout table for investigator information
Principal Investigator: Marie-Eve Bergeron, MD CHUL (CHUdeQuebec) - Département d'endocrinologie de la reproduction
Layout table for additonal information
Responsible Party: CHU de Quebec-Universite Laval Identifier: NCT03435809    
Other Study ID Numbers: CHUdeQuebec
First Posted: February 19, 2018    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female